Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending July 06, 2006. The report serves as a notification of transactions involving directors and persons discharging managerial responsibility under the US Retirement Savings Plan.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on share allocation notifications within a retirement plan.
Material Changes
Material changes reported relate to the notional allocation of GSK Ordinary Share ADRs within the US Retirement Savings Plan following a re-valuation of the cash element:
- Dr M Slaoui: Notified of an increase in notional allocation on June 30, 2006, at a price of $55.80 per share.
- Dr R Greig: Notified of a decrease in notional allocation on June 30, 2006, at a price of $55.80 per share.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It is a compliance notification pursuant to Disclosure Rule 3.1.4R(1)(a).
Investor Verification Points
- Verify the specific number of shares involved in the increase for Dr M Slaoui and the decrease for Dr R Greig, as the text only lists the price ($55.80) and the direction of change.
- Confirm the total notional holdings of these individuals post-transaction to assess potential insider trading implications or concentration risks.
- Review the full US Retirement Savings Plan rules to understand the mechanics of the "notional investment" and re-valuation process described.